AstraZeneca partners with insitro on AI-driven drug discovery for MASH, cardiomyopathies

(AWP Alliance News) - AstraZeneca entered a strategic drug discovery collaboration and licensing agreement with insitro to develop AI-driven treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will use its AI platform to identify disease drivers and advance selected targets to development candidates.

Insitro will receive USD 40 million upfront and could earn up to approximately USD 1.46 billion in development and commercial milestone payments. It is also eligible for single-digit royalties on global commercial sales.

AstraZeneca will hold exclusive worldwide rights to advance selected programs identified through the collaboration.

https://www.publicnow.com/view/A998F5C713229722DD7650155155C10CAF020DB7…

Disclaimer: This news brief was created using generative artificial intelligence. AstraZeneca plc published the original content used to generate this news brief via Cision on October 15, 2026, and is solely responsible for the information contained therein.